Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. Swiss pharma giant Roche won approval from the ...
Two experimental drug molecules promoted myelin repair in MS disease models, pointing toward a possible future route for ...
After years of legal wrangling surrounding Teva’s Copaxone, the latest hit to the lucrative multiple sclerosis drug comes in the form of a safety-related boxed warning. The label update, which also ...
Copaxone (glatiramer acetate) may not be safe to receive while pregnant or breastfeeding. Certain factors, including the risks of fetal harm, may determine whether you can receive the drug during this ...
Jan 22 (Reuters) - The U.S. Food and Drug Administration on Wednesday warned about the risk of a rare but serious allergic reaction with the use of some multiple sclerosis drugs including Teva's (TEVA ...
(Reuters) - Mylan NV's long-awaited U.S. approval for its generic version of rival Teva's blockbuster multiple sclerosis treatment Copaxone drove Mylan's shares up around 18 percent on Wednesday while ...
Beginning 23 March, the US Food and Drug Administration (FDA) is going to convert more than 100 medicines approved under new drug applications (NDAs) to biologics license applications (BLAs) because ...
ZURICH, April 22 (Reuters) - Swiss drugmaker Roche on Wednesday said it was submitting its experimental multiple sclerosis drug fenebrutinib to global regulators after meeting late-stage trial goals ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results